Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Philogen SpA ( (IT:PHIL) ) just unveiled an announcement.
Philogen S.p.A. has announced an update on its share buyback program, revealing the purchase of 4,524 shares from May 7 to May 9, 2025, representing 0.0111% of its share capital at an average price of Euro 21.80 per share. This move is part of a broader strategy approved by the Board of Directors and Shareholders’ Meeting, reflecting the company’s commitment to enhancing shareholder value. As of May 9, 2025, Philogen holds a total of 336,674 ordinary shares, equating to 0.8290% of its share capital, indicating a strategic approach to managing its equity and potentially impacting its market positioning.
The most recent analyst rating on (IT:PHIL) stock is a Buy with a EUR25.00 price target. To see the full list of analyst forecasts on Philogen SpA stock, see the IT:PHIL Stock Forecast page.
More about Philogen SpA
Philogen is an Italian-Swiss biotechnology company specializing in the research and development of pharmaceutical products aimed at treating diseases with high mortality rates. The company focuses on creating targeted anti-cancer drugs using high-affinity ligands for tumor markers, employing technologies such as Antibody Phage Display Libraries and DNA-Encoded Chemical Libraries. Philogen’s main therapeutic strategy involves tumor targeting, which selectively delivers potent therapeutic agents to tumors while sparing healthy tissues. The company aims to develop and commercialize innovative products for diseases lacking satisfactory therapies, with a primary focus on oncological applications.
YTD Price Performance: 11.79%
Average Trading Volume: 8,774
Technical Sentiment Signal: Buy
Current Market Cap: €637.5M
For an in-depth examination of PHIL stock, go to TipRanks’ Stock Analysis page.